Stifel Reiterates Mirati (MRTX) at Buy, adagrasib Approval is Likely, But Shares May be Weak as Drug Was Not Accepted For Priority Review
Tweet Send to a Friend
Stifel analyst Ben Burnett reiterated a Buy rating on Mirati Therapeutics (NASDAQ: MRTX), following announcement that the FDA has set ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
